Read-Gene (WAR:RDG) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:RDG Read-Gene SA WAR:RDG
80 GF Score
Price zł4.86
GF Value zł6.37
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Read-Gene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

WAR:RDG vs VRTX, REGN, RVMD: Short Interest Comparison

For the Biotechnology subindustry, Read-Gene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Read-Gene Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Read-Gene's Short Interest distribution charts can be found below:

* The bar in red indicates where Read-Gene's Short Interest falls into.


WAR:RDG
80GF Score
Read-Gene SA WAR:RDG
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Read-Gene (WAR:RDG) Overvalued in 2026?

Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued. The current stock price of zł4.86 is trading 23.7% below its estimated GF Value™ of zł6.37. GuruFocus considers Read-Gene to be Modestly Undervalued.

Key valuation signals for WAR:RDG:

  • Short Interest:
  • GF Value™: zł6.37 vs. price of zł4.86 (23.7% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Read-Gene Business Description

Address Ulica Alabastrowa 8, Grzepnica, Dobra, POL, 72-003
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
80GF Score

Get the complete analysis for WAR:RDG

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł4.86
Price
zł6.37
GF Value